BR112017018533A2 - dispersões sólidas - Google Patents

dispersões sólidas

Info

Publication number
BR112017018533A2
BR112017018533A2 BR112017018533A BR112017018533A BR112017018533A2 BR 112017018533 A2 BR112017018533 A2 BR 112017018533A2 BR 112017018533 A BR112017018533 A BR 112017018533A BR 112017018533 A BR112017018533 A BR 112017018533A BR 112017018533 A2 BR112017018533 A2 BR 112017018533A2
Authority
BR
Brazil
Prior art keywords
ospemifene
methods
acetate
polyvinylpyrrolidine
treating
Prior art date
Application number
BR112017018533A
Other languages
English (en)
Other versions
BR112017018533B1 (pt
Inventor
Halloran Kevin
Chen Xiaoming
Chen Zhengming
Original Assignee
Shionogi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi Inc filed Critical Shionogi Inc
Publication of BR112017018533A2 publication Critical patent/BR112017018533A2/pt
Publication of BR112017018533B1 publication Critical patent/BR112017018533B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a uma dispersão sólida de ospemifeno para aumentar sua solubilidade e biodisponibilidade, e a métodos de preparação dessa dispersão. a dispersão sólida compreende um in-grediente farmacêutico ativo, tal como ospemifeno, e um veículo hidrófilo, tais como copovidona, acetato succinato de hipromelose, polivinilpirrolidina, um copolímero de polivinilpirrolidina/acetato de vinila, hidroxilpropilmetilcelulose, acetato succinato de hipromelose, um composto de eudragit®, hidroxipropilcelulose, um copolímero de enxerto polivinil caprolactama-acetato de polivinil polietilenoglicol, ftalato de hidroxipropilmetilcelulose e suas misturas, e, opcionalmente, um tensoativo. as dispersões sólidas de ospemifeno podem ser usadas em métodos de tratamento de um sintoma relacionado com a menopausa, tal como secura vaginal ou disfunção sexual, ou em métodos de tratamento de osteoporose.
BR112017018533-4A 2015-03-10 2016-03-10 Composição que compreende uma dispersão sólida de ospemifeno e seu método de preparação BR112017018533B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131060P 2015-03-10 2015-03-10
US62/131,060 2015-03-10
PCT/US2016/021671 WO2016145138A1 (en) 2015-03-10 2016-03-10 Solid dispersions

Publications (2)

Publication Number Publication Date
BR112017018533A2 true BR112017018533A2 (pt) 2018-04-24
BR112017018533B1 BR112017018533B1 (pt) 2023-10-03

Family

ID=56879338

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018533-4A BR112017018533B1 (pt) 2015-03-10 2016-03-10 Composição que compreende uma dispersão sólida de ospemifeno e seu método de preparação

Country Status (12)

Country Link
US (1) US10596118B2 (pt)
EP (1) EP3270696B1 (pt)
JP (1) JP6453482B2 (pt)
KR (1) KR102055542B1 (pt)
CN (1) CN107529758B (pt)
AU (1) AU2016229086B2 (pt)
BR (1) BR112017018533B1 (pt)
CA (1) CA2976811C (pt)
ES (1) ES2960344T3 (pt)
MX (1) MX2017011469A (pt)
RU (1) RU2694832C2 (pt)
WO (1) WO2016145138A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102526A1 (en) * 2016-12-01 2018-06-07 Glaxosmithkline Llc Pharmaceutical dosage form
CA3066046A1 (en) 2017-07-04 2019-01-10 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition and method for preparing same
US20210308116A1 (en) * 2018-07-13 2021-10-07 Council Of Scientific And Industrial Research Solid dispersion comprising an anticancer compound for improved solubility and efficacy
MX2021005764A (es) * 2018-11-16 2021-10-01 Jiangsu Hengrui Medicine Co Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp).
CA3151612A1 (en) * 2019-09-19 2021-03-25 George P. Luke Pyruvate kinase r (pkr) activating compositions
WO2022034914A1 (ja) * 2020-08-13 2022-02-17 カルナバイオサイエンス株式会社 易溶性固形製剤およびその製法
CN112263567B (zh) * 2020-10-19 2022-05-03 南京易亨制药有限公司 一种布洛芬缓释胶囊及制备方法
CN113149023B (zh) * 2021-03-11 2023-05-02 昆明理工大学 一种介孔二氧化硅纳米颗粒经皮递送低共熔体系制备方法
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion
CN115429766B (zh) * 2022-09-08 2023-10-27 江苏集萃新型药物制剂技术研究所有限公司 淫羊藿苷固体分散体、复方药物双层片剂及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1361867B1 (en) 2001-02-22 2007-03-21 Jagotec AG Fibrate-statin combinations with reduced fed-fasted effects
US20040005339A1 (en) 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
PT1748756E (pt) * 2004-03-10 2009-07-20 Bayer Schering Pharma Ag Composições compreendendo drospirenona molecularmente dispersa
BRPI0509381A (pt) * 2004-04-08 2007-09-18 Wyeth Corp dispersão sólida, métodos de preparar a dispersão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência ou o excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal de tecidos endometrais, de tratar cáncer de mamas de um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, composição, forma de dosagem, e, uso de uma dispersão sólida
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
ATE545411T1 (de) * 2008-03-25 2012-03-15 Formac Pharmaceuticals N V Herstellungsverfahren für feststoffdispersionen
US20090324714A1 (en) * 2008-06-27 2009-12-31 Wyeth Dual adhesive technology
US20100028403A1 (en) 2008-07-31 2010-02-04 Boston Scientific Scimed, Inc. Medical devices for therapeutic agent delivery
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
JP2014503470A (ja) 2010-10-14 2014-02-13 アボット ゲーエムベーハー ウント カンパニー カーゲー クルクミノイド固体分散製剤
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
JP5854804B2 (ja) 2011-07-08 2016-02-09 ダンロップスポーツ株式会社 ゴルフボール用樹脂組成物およびゴルフボール
US20150011525A1 (en) * 2011-09-13 2015-01-08 Isp Investments Inc. Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
US20160000732A1 (en) * 2014-07-02 2016-01-07 Cadila Healthcare Limited Oral pharmaceutical compositions of ospemifene

Also Published As

Publication number Publication date
CA2976811A1 (en) 2016-09-15
CN107529758A (zh) 2018-01-02
US10596118B2 (en) 2020-03-24
RU2017128887A (ru) 2019-04-10
KR20170125944A (ko) 2017-11-15
RU2694832C2 (ru) 2019-07-17
EP3270696A4 (en) 2018-12-05
MX2017011469A (es) 2018-01-23
AU2016229086A1 (en) 2017-08-31
WO2016145138A1 (en) 2016-09-15
US20180036245A1 (en) 2018-02-08
CA2976811C (en) 2023-06-27
JP6453482B2 (ja) 2019-01-16
ES2960344T3 (es) 2024-03-04
BR112017018533B1 (pt) 2023-10-03
AU2016229086B2 (en) 2018-12-06
EP3270696B1 (en) 2023-09-06
EP3270696C0 (en) 2023-09-06
KR102055542B1 (ko) 2019-12-13
CN107529758B (zh) 2021-01-26
EP3270696A1 (en) 2018-01-24
JP2018507896A (ja) 2018-03-22
RU2017128887A3 (pt) 2019-04-10

Similar Documents

Publication Publication Date Title
BR112017018533A2 (pt) dispersões sólidas
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
MY189601A (en) Treatment of beta-thalassemia using actrii ligand traps
PH12018501072A1 (en) Modified release orally administered amino acid formulations
SG11201808019WA (en) Edaravone formulations
DOP2016000262A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
NZ723859A (en) Pharmaceutical compositions of therapeutically active compounds and their uses
NZ723860A (en) Pharmaceutical compositions of therapeutically active compounds and their uses
EA201390194A1 (ru) Улучшенный рекомбинантный фолликул-стимулирующий гормон человека
MX2018000016A (es) Composiciones farmaceuticas liofilizadas.
MX370628B (es) Composiciones y metodos para tratar las espinillas.
MX2018003711A (es) Anillo de mezclado para disolver una porcion de soluto en una porcion de solvente, sistema y metodo para disolver una porcion de soluto en una porcion de solvente.
IN2014MU00303A (pt)
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
PH12016501841A1 (en) Immunosuppressant formulation
IN2014MU01042A (pt)
MX2016014346A (es) Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada.
MX2017003638A (es) Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
MX2021002633A (es) Dispersiones solidas de bendamustina e infusion continua.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2018011422A (es) Farmaco de sal cristalina de clorhidrato para tratar o prevenir enfermedad asociada con janus cinasas (jak) y su metodo de preparacion.
BR112017019364A2 (pt) dispersões sólidas
MX2017004242A (es) Prueba de disolucion de ingredientes activos farmaceuticos hidrofobicos tal como avermectinas con o sin pirantel.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 57/00

Ipc: A61K 31/085 (2006.01), A61K 47/32 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2016, OBSERVADAS AS CONDICOES LEGAIS